IL6 and COVID-19: On the other hand, despite the association of high IL-6 levels with shorter survival and the evidence that laboratory findings of hyperinflammation (example, elevated values of C-reactive protein—CRP) and tissue damage predict worsening outcomes in COVID-19, data for anti–IL-6 receptor antibody therapies lack a uniform confirmation and/or are still insufficient, and are thus reported as conflicting in terms of mortality and hospitalization.